Co-Founder and former COO/CMO/Director of PolarityTE Inc. (Nasdaq: PTE); over 18 years in biomedical research including oncology, transplant immunology, cell therapy, and neuroscience; Plastic and Reconstructive Surgery Residency at Johns Hopkins/Univ of Maryland/Shock Trauma; MD from Harvard Medical School with honors; Bioengineering at University of Pennsylvania with honors

Over 30 years of commercial experience in biotech and pharma including VP/GM of ArgenX Inc., and VP/GM roles for biotech startups in Ultrarare Disease, Neurometabolics, Hematology and Gene Therapy including Orchard Therapeutics and Sucampo; started at Alexion pre-commercial and grew to lead U.S. Complement Team >$1.5B; increasing leadership at BMS, Biogen, Celgene, Amgen, and Roche

Founder of QRAL Group, a management consulting firm working with top 100 pharma and biotech companies across >50 countries in commercial design, operations, business expansion, licensing deals, and major pharmaceutical M&A. Prior scientific research leading to the discovery and development of Angiomax (bivalirudin; Nycomed Pharma AS) and Retavase (BM06.022, recombinant tissue plasminogen activator; Boehringer Mannheim).

Co-Founder/CIO of Twin Keel Capital an asset management firm focused on systematically managed investment strategies, Over 15 years of experience at Fidelity Institutional Asset Management focused on Healthcare investing, most recently as a Senior Healthcare Analyst on the Small Cap Team, BBA from U Michigan Ross School of Business

Chief Commercial Officer and founding member of Biohaven Pharmaceuticals; Board of Directors of Hemoshear Pharmaceuticals; Executive Director and one of the founding commercial leaders of Alexion Pharmaceuticals, Inc. with central role in the successful global launches of Soliris and operational infrastructure for 4 orphan indication launches in over 30 countries; increasing leadership roles at Pfizer, Agouron and Sanofi; BS in Business Administration from the University of South Carolina — Darla Moore School of Business